Thelansis

 Cervical cancer ranks among the most prevalent malignancies affecting the female reproductive system. It stands as the second leading cause of cancer-related deaths in women aged 20 to 39. The prognosis for cervical cancer patients, especially those in advanced stages, remains grim. Human papillomavirus (HPV) infects the majority of sexually active individuals at some point in their lives. There exist more than 130 distinct HPV types, with 20 of them associated with cancer. The rates of HPV-related cervical dysplasia are only documented in women. The most frequently encountered HPV strains in invasive cervical cancer are HPV 16 and 18. Risk factors for HPV and cervical cancer encompass factors such as the age at first sexual intercourse, having multiple sexual partners, smoking, herpes simplex infection, HIV infection, co-infection with other genital infections, and the use of oral contraceptives. HPV spreads through skin-to-skin contact, including sexual intercourse, hand-to-genital

 Cervical cancer is one of the most common malignancies in the female genital tract system. It is the second leading cause of cancer mortality in women aged 20 to 39 years. The prognosis of cervical cancer patients remains poor, especially in metastatic patients. Previous studies have shown that the median survival time of metastatic cervical cancer is only 8-13 months, and the 5-year survival rate is 16.5%. Due to the poor prognosis, metastatic cervical cancer has become one of the main challenges in the world. In metastatic and recurrent Cervical cancer, Single-site metastasis accounted for 68.7%, and multi-organ metastases were relatively rare. In single-site metastasis, lung metastasis was the most common, accounting for 37.9% of all patients, followed by bone metastasis (16.7%) and liver metastasis (12.5%). ·        Brain metastases were uncommon, only accounted for 1.6%. In patients with multi-organ metastases, lung plus liver metastases and lung plus bone metastases were more